The European Medicines Agency (EMA) said on September 6 that it had started evaluating an application for the use of a booster dose of Comirnaty to be given six months after the second dose in people aged 16 years and older.
Cominarty is the Pzifer-BioNTech vaccine against Covid-19.
Booster doses are given to vaccinated people, that is people who have completed their primary vaccination, to restore protection after it has waned, the EMA said.
“EMA’s human medicines committee (CHMP) will carry out an accelerated assessment of data submitted by the company that markets Comirnaty, including results from an ongoing clinical trial in which around 300 adults with healthy immune systems received a booster dose approximately six months after the second dose,” it said.
The CHMP will recommend whether updates to the product information are appropriate. The outcome of this evaluation is expected within the next few weeks, unless supplementary information is needed, and will be communicated by EMA.
Separately, EMA is also assessing data from the literature on the use of an additional, third dose of an mRNA vaccine (Comirnaty or SpikeVax) in severely immunocompromised people, that is, those with weakened immune systems).
People with severely weakened immune systems who do not achieve an adequate level of protection from their standard primary vaccination may need an “additional” dose as part of their primary vaccination, the agency said.
EMA will also communicate on the outcome of these evaluations in due course.
While these evaluations are ongoing, EMA and the European Centre for Disease Prevention and Control (ECDC) have highlighted their current position regarding the need for additional and booster doses of COVID-19 vaccines in a separate communication.
“Although EMA and ECDC do not consider the need for Covid-19 vaccine booster doses to be urgent in the general population, EMA is evaluating the present application to ensure evidence is available to support further doses as necessary.”
The EMA said that advice on how vaccinations should be given remains the prerogative of the national immunisation technical advisory groups (NITAGs) guiding the vaccination campaigns in each EU country. While EMA assesses relevant data, EU countries may already consider preparatory plans for administering boosters and additional doses, the agency said.
(Photo via the Facebook page of Bulgaria’s Health Ministry)
For the rest of The Sofia Globe’s continuing coverage of the Covid-19 situation in Bulgaria, please click here.
The Sofia Globe’s coverage of the Covid-19 situation in Bulgaria is supported by the Embassies of Switzerland and Finland.
Please support independent journalism by clicking on the orange button below. For as little as three euro a month or the equivalent in other currencies, you can support The Sofia Globe via patreon.com: